The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Next Generation Medicines

Forums General Melanoma Community Next Generation Medicines

  • Post
    rick1981
    Participant

      Hi everyone,

      It seems like progress on cancer/melanoma treatment is moving at an incredible pace – which is a good thing. When my wife was diagnosed with Stage IV in June, our oncologist referred to Nivolumab as that "wonder medicine" he'd which he'd have access to – and only a couple of months later Pembrolizumab has been approved in the US and Expanded Access has open in Europe and Nivolumab is not far behind.

      It's great to have options after the BRAF/MEK inhibitors (or in the future maybe as first line), but it thought it would be good as well to think even further out and look at what medicines may be next up in the Big Pharma's pipeline – so we can discuss this & potential trials with our oncologists.

      So therefore this topic ๐Ÿ™‚

      (If it already exists, please point me in the right direction and this one can be closed).

      The two melanoma medicines that have come to my attention very recently are:

      BAVITUXIMAB: http://money.cnn.com/news/newsfeeds/articles/marketwire/1149321.htm. "statistically significant tumor growth suppression compared to anti-PD-1 antibody treatment alone in an animal model of melanoma". Trial with Yervoy/Ipi being started.

      LIRILUMAB: http://www.mskcc.org/cancer-care/trial/12-224 Trial with Nivo. Ashley here on MPIP has mentioned this trial.

      Good to know who's on these trials, what other medicines are being tested – and in the future to keep each other posted on Trial outcomes.

      Best regards, Rick

       

       

       

       

       

    Viewing 2 reply threads
    • Replies
        G-Samsa
        Participant

          On the immunotherapy beat I keep hearing about IDO inhibitors and Lag-3 as showing great promise as a next gen treatment.   There is also a chemo-therapy (ADC) that was getting a lot of press at one point–informed by genetics it delivers the cytotoxin directly to the tumor.  It would be nice to have an update on that.  Way down the pike but high on the imaginative scale–Yale Cancer Center has successfully used a virus to attack melanoma in mice (lucky mice).  I believe there are quite a number of other treatments being tested…. 

          G-Samsa
          Participant

            On the immunotherapy beat I keep hearing about IDO inhibitors and Lag-3 as showing great promise as a next gen treatment.   There is also a chemo-therapy (ADC) that was getting a lot of press at one point–informed by genetics it delivers the cytotoxin directly to the tumor.  It would be nice to have an update on that.  Way down the pike but high on the imaginative scale–Yale Cancer Center has successfully used a virus to attack melanoma in mice (lucky mice).  I believe there are quite a number of other treatments being tested…. 

              arthurjedi007
              Participant

                Is ADC antibody drug conjugates? If so I got very disappointed when someone on here posted the results of their phase 2 trial. Although the results were pretty good with if I remember right it was in the 30s percent receiving clinical benefit the company cancelled it. Maybe someone will pick it up again and maybe even improve it. That was my plan B back then. Sorry I didn't keep the url to the article on it.

                There's also another type of chemo with this phase 1 trial NCT02020707. One of it's chemo back in 2009 was being compared with zelboraf. This trial combines it with some others as well.

                There is also TIL in a phase 2 trial and several phase 1 trials with a rumor of a big trial for it coming in 2015.

                Also is WDVAX in a phase 1 trial. I have not heard anyone doing it or results but it's pre trial with mice was awesome results. Of course we don't know yet how that will translate to us humans. They are also working on a less invasive delivery system instead of surgical implants they are working on a type of gel to inject the scaffold in with and some other ideas.

                Also here's an article on the various mutations that makes my head spin:

                http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=1892&path%5B%5D=2533

                Artie

                 

                 

                oldblue
                Participant

                   

                  The learned people at the Melanoma Institute in Sydney are very hopeful of further developments coming on track and speak of combination treatments working in several ways as the path forward. They talk of first line combinations and second line combinations and treating peoplemore aggressively with adjuvant drugs much earlier.

                  I can remember HAART studies for HIV decades ago. The results were so astonishing that the trials were immediatly stopped and anti HIV drugs were fast tacked into production. I was caring for people with HIV at the time and was watching them preparefor their impending deaths. Some of them are still alive 20 years later. Some moaned that they had to find a job again because they were so well on the new combination therapies. The profits these drugs generate are probably helping to fund research into melanoma.

                  I may be delusional but melanoma does seem to me have the same sense of excitement amongst the few scientists I have spoken to as anti HIV drugs did. Given the time lag on trials and approvals, in three to five years it will be a different ball game,it seems to me. In HIV the problem was one of viral mutation. I may be wrong but in melanoma it seems to be the number of different genetic pathways open to cells to take to replicate is a big challenge and that is why the drugs only seem to work for a certain amount of time – but I am no scientist. I'm sure many who post know much more than I do.

                  I'm currently stage 3b and have been told I am considered high risk to further progression. I'm not sure how that is defined, and maybe everyone at 3b is high risk, but there you go. Statistically, I have been told I have a 48% chance of surviving 5 years. I think if I am lucky to get to five years, there just might be better combination therapies there for everyone with this diagnosis.

                   

                   

                   

                  rick1981
                  Participant

                    Hi all,

                    Here two new development in the field of melanoma:

                    http://www.medicaldaily.com/scientists-discover-new-melanoma-cell-subpopulation-blame-drug-resistant-tumors-307654

                    http://www.forbes.com/sites/jonfortenbury/2014/10/29/a-new-cancer-drug-worked-in-over-50-of-patients-in-a-phase-ii-trial/

                    So summarizing what seems to be promising are:
                    – Bavituximab (immuno theraphy)
                    – Bevacizumab/Avastin (angiogenesis inhibitor, VEGF targeter)
                    – Lirilumab (anti-KIR: killer-cell immunoglobulin-like receptors)
                    – Anti-angiogenic therapies: http://www.medicaldaily.com/scientists- … ors-307654
                    – PV-10 (Intralesional)

                    Good to keep following these!

                     

                    rick1981
                    Participant

                      Hi all,

                      Here two new development in the field of melanoma:

                      http://www.medicaldaily.com/scientists-discover-new-melanoma-cell-subpopulation-blame-drug-resistant-tumors-307654

                      http://www.forbes.com/sites/jonfortenbury/2014/10/29/a-new-cancer-drug-worked-in-over-50-of-patients-in-a-phase-ii-trial/

                      So summarizing what seems to be promising are:
                      – Bavituximab (immuno theraphy)
                      – Bevacizumab/Avastin (angiogenesis inhibitor, VEGF targeter)
                      – Lirilumab (anti-KIR: killer-cell immunoglobulin-like receptors)
                      – Anti-angiogenic therapies: http://www.medicaldaily.com/scientists- … ors-307654
                      – PV-10 (Intralesional)

                      Good to keep following these!

                       

                      rick1981
                      Participant

                        Hi all,

                        Here two new development in the field of melanoma:

                        http://www.medicaldaily.com/scientists-discover-new-melanoma-cell-subpopulation-blame-drug-resistant-tumors-307654

                        http://www.forbes.com/sites/jonfortenbury/2014/10/29/a-new-cancer-drug-worked-in-over-50-of-patients-in-a-phase-ii-trial/

                        So summarizing what seems to be promising are:
                        – Bavituximab (immuno theraphy)
                        – Bevacizumab/Avastin (angiogenesis inhibitor, VEGF targeter)
                        – Lirilumab (anti-KIR: killer-cell immunoglobulin-like receptors)
                        – Anti-angiogenic therapies: http://www.medicaldaily.com/scientists- … ors-307654
                        – PV-10 (Intralesional)

                        Good to keep following these!

                         

                        rick1981
                        Participant

                          Ah one surprising route I heard about the radio recently…. ALPACA immunity boosters. I'm sure you wouldn't believe me if Merck hadn't just signed a licensing deal with this Belgian/Dutch company: http://www.google.com/url?url=http://www.ft.com/cms/s/0/6b5d31fe-8bf5-11e3-bcf2-00144feab7de.html&rct=j&frm=1&q=&esrc=s&sa=U&ei=hUlTVI-THISE7gbO94HQDw&ved=0CBQQFjAA&sig2=681Eyu9x2j2bsqldkPtS_Q&usg=AFQjCNEhZnAn0RDVw-fVDC6H8VMoY6Yyqg ๐Ÿ™‚

                          The explained in the show that some lab researcher by accident found that alpacas have extremely well developed immune systems. And that if you place a human cancer cell into the alpaca, the cancer cell gets destroyed while the alpaca is not harmed. If only we could have that immune system, right?! So that's what's this company is exploring….

                          rick1981
                          Participant
                            rick1981
                            Participant

                              And yet another piece of news on treatment options: Ipi plus Leukine

                              http://time.com/3558659/cancer-treatment-immunotherapy/

                              rick1981
                              Participant

                                Hi all,

                                This is what our MD had to say about 2 recent studies:

                                "[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"

                                "The anti-KIR treatment plus nivolumab is promising but still in phase 1 research. The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"

                                rick1981
                                Participant

                                  CORRECTION TO PREVIOUS POST:

                                  Hi all,

                                  This is what our MD had to say about 3 recent studies:

                                  "[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"

                                  "The [b]anti-KIR treatment (Lirilumab)[/b] plus nivolumab is promising but still in phase 1 research".

                                  "The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"

                                  rick1981
                                  Participant

                                    CORRECTION TO PREVIOUS POST:

                                    Hi all,

                                    This is what our MD had to say about 3 recent studies:

                                    "[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"

                                    "The [b]anti-KIR treatment (Lirilumab)[/b] plus nivolumab is promising but still in phase 1 research".

                                    "The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"

                                    rick1981
                                    Participant

                                      CORRECTION TO PREVIOUS POST:

                                      Hi all,

                                      This is what our MD had to say about 3 recent studies:

                                      "[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"

                                      "The [b]anti-KIR treatment (Lirilumab)[/b] plus nivolumab is promising but still in phase 1 research".

                                      "The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"

                                      kylez
                                      Participant

                                        thanks Rick – appreciate you passing on your doc's assessments.

                                        kylez
                                        Participant

                                          thanks Rick – appreciate you passing on your doc's assessments.

                                          rick1981
                                          Participant

                                            http://www.coloradocancerblogs.org/next-gen-melanoma-drug-tak-733-excels-lab-tests/

                                            Promising early results on 2nd generation BRAF/MEK inhibitor

                                            rick1981
                                            Participant

                                              http://www.coloradocancerblogs.org/next-gen-melanoma-drug-tak-733-excels-lab-tests/

                                              Promising early results on 2nd generation BRAF/MEK inhibitor

                                              rick1981
                                              Participant

                                                http://www.coloradocancerblogs.org/next-gen-melanoma-drug-tak-733-excels-lab-tests/

                                                Promising early results on 2nd generation BRAF/MEK inhibitor

                                                kylez
                                                Participant

                                                  thanks Rick – appreciate you passing on your doc's assessments.

                                                  rick1981
                                                  Participant

                                                    Hi all,

                                                    This is what our MD had to say about 2 recent studies:

                                                    "[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"

                                                    "The anti-KIR treatment plus nivolumab is promising but still in phase 1 research. The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"

                                                    rick1981
                                                    Participant

                                                      Hi all,

                                                      This is what our MD had to say about 2 recent studies:

                                                      "[b]Ipilimumab plus GM-CSF (sargramostim)[/b] phase III results are controversial because although the OS improves the PFS does not. So taking into account the anti-PD1 treatments, this doesn't really make any changes to the theurapeutic strategy"

                                                      "The anti-KIR treatment plus nivolumab is promising but still in phase 1 research. The anti-VEGF seems to improve the impact of ipi but not that of anti-PD-L1 plus [b]Bevacizumab/Avastin[/b]"

                                                      rick1981
                                                      Participant

                                                        And yet another piece of news on treatment options: Ipi plus Leukine

                                                        http://time.com/3558659/cancer-treatment-immunotherapy/

                                                        rick1981
                                                        Participant

                                                          And yet another piece of news on treatment options: Ipi plus Leukine

                                                          http://time.com/3558659/cancer-treatment-immunotherapy/

                                                          rick1981
                                                          Participant
                                                            rick1981
                                                            Participant
                                                              rick1981
                                                              Participant

                                                                Ah one surprising route I heard about the radio recently…. ALPACA immunity boosters. I'm sure you wouldn't believe me if Merck hadn't just signed a licensing deal with this Belgian/Dutch company: http://www.google.com/url?url=http://www.ft.com/cms/s/0/6b5d31fe-8bf5-11e3-bcf2-00144feab7de.html&rct=j&frm=1&q=&esrc=s&sa=U&ei=hUlTVI-THISE7gbO94HQDw&ved=0CBQQFjAA&sig2=681Eyu9x2j2bsqldkPtS_Q&usg=AFQjCNEhZnAn0RDVw-fVDC6H8VMoY6Yyqg ๐Ÿ™‚

                                                                The explained in the show that some lab researcher by accident found that alpacas have extremely well developed immune systems. And that if you place a human cancer cell into the alpaca, the cancer cell gets destroyed while the alpaca is not harmed. If only we could have that immune system, right?! So that's what's this company is exploring….

                                                                rick1981
                                                                Participant

                                                                  Ah one surprising route I heard about the radio recently…. ALPACA immunity boosters. I'm sure you wouldn't believe me if Merck hadn't just signed a licensing deal with this Belgian/Dutch company: http://www.google.com/url?url=http://www.ft.com/cms/s/0/6b5d31fe-8bf5-11e3-bcf2-00144feab7de.html&rct=j&frm=1&q=&esrc=s&sa=U&ei=hUlTVI-THISE7gbO94HQDw&ved=0CBQQFjAA&sig2=681Eyu9x2j2bsqldkPtS_Q&usg=AFQjCNEhZnAn0RDVw-fVDC6H8VMoY6Yyqg ๐Ÿ™‚

                                                                  The explained in the show that some lab researcher by accident found that alpacas have extremely well developed immune systems. And that if you place a human cancer cell into the alpaca, the cancer cell gets destroyed while the alpaca is not harmed. If only we could have that immune system, right?! So that's what's this company is exploring….

                                                                  oldblue
                                                                  Participant

                                                                     

                                                                    The learned people at the Melanoma Institute in Sydney are very hopeful of further developments coming on track and speak of combination treatments working in several ways as the path forward. They talk of first line combinations and second line combinations and treating peoplemore aggressively with adjuvant drugs much earlier.

                                                                    I can remember HAART studies for HIV decades ago. The results were so astonishing that the trials were immediatly stopped and anti HIV drugs were fast tacked into production. I was caring for people with HIV at the time and was watching them preparefor their impending deaths. Some of them are still alive 20 years later. Some moaned that they had to find a job again because they were so well on the new combination therapies. The profits these drugs generate are probably helping to fund research into melanoma.

                                                                    I may be delusional but melanoma does seem to me have the same sense of excitement amongst the few scientists I have spoken to as anti HIV drugs did. Given the time lag on trials and approvals, in three to five years it will be a different ball game,it seems to me. In HIV the problem was one of viral mutation. I may be wrong but in melanoma it seems to be the number of different genetic pathways open to cells to take to replicate is a big challenge and that is why the drugs only seem to work for a certain amount of time – but I am no scientist. I'm sure many who post know much more than I do.

                                                                    I'm currently stage 3b and have been told I am considered high risk to further progression. I'm not sure how that is defined, and maybe everyone at 3b is high risk, but there you go. Statistically, I have been told I have a 48% chance of surviving 5 years. I think if I am lucky to get to five years, there just might be better combination therapies there for everyone with this diagnosis.

                                                                     

                                                                     

                                                                     

                                                                    oldblue
                                                                    Participant

                                                                       

                                                                      The learned people at the Melanoma Institute in Sydney are very hopeful of further developments coming on track and speak of combination treatments working in several ways as the path forward. They talk of first line combinations and second line combinations and treating peoplemore aggressively with adjuvant drugs much earlier.

                                                                      I can remember HAART studies for HIV decades ago. The results were so astonishing that the trials were immediatly stopped and anti HIV drugs were fast tacked into production. I was caring for people with HIV at the time and was watching them preparefor their impending deaths. Some of them are still alive 20 years later. Some moaned that they had to find a job again because they were so well on the new combination therapies. The profits these drugs generate are probably helping to fund research into melanoma.

                                                                      I may be delusional but melanoma does seem to me have the same sense of excitement amongst the few scientists I have spoken to as anti HIV drugs did. Given the time lag on trials and approvals, in three to five years it will be a different ball game,it seems to me. In HIV the problem was one of viral mutation. I may be wrong but in melanoma it seems to be the number of different genetic pathways open to cells to take to replicate is a big challenge and that is why the drugs only seem to work for a certain amount of time – but I am no scientist. I'm sure many who post know much more than I do.

                                                                      I'm currently stage 3b and have been told I am considered high risk to further progression. I'm not sure how that is defined, and maybe everyone at 3b is high risk, but there you go. Statistically, I have been told I have a 48% chance of surviving 5 years. I think if I am lucky to get to five years, there just might be better combination therapies there for everyone with this diagnosis.

                                                                       

                                                                       

                                                                       

                                                                      arthurjedi007
                                                                      Participant

                                                                        Is ADC antibody drug conjugates? If so I got very disappointed when someone on here posted the results of their phase 2 trial. Although the results were pretty good with if I remember right it was in the 30s percent receiving clinical benefit the company cancelled it. Maybe someone will pick it up again and maybe even improve it. That was my plan B back then. Sorry I didn't keep the url to the article on it.

                                                                        There's also another type of chemo with this phase 1 trial NCT02020707. One of it's chemo back in 2009 was being compared with zelboraf. This trial combines it with some others as well.

                                                                        There is also TIL in a phase 2 trial and several phase 1 trials with a rumor of a big trial for it coming in 2015.

                                                                        Also is WDVAX in a phase 1 trial. I have not heard anyone doing it or results but it's pre trial with mice was awesome results. Of course we don't know yet how that will translate to us humans. They are also working on a less invasive delivery system instead of surgical implants they are working on a type of gel to inject the scaffold in with and some other ideas.

                                                                        Also here's an article on the various mutations that makes my head spin:

                                                                        http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=1892&path%5B%5D=2533

                                                                        Artie

                                                                         

                                                                         

                                                                        arthurjedi007
                                                                        Participant

                                                                          Is ADC antibody drug conjugates? If so I got very disappointed when someone on here posted the results of their phase 2 trial. Although the results were pretty good with if I remember right it was in the 30s percent receiving clinical benefit the company cancelled it. Maybe someone will pick it up again and maybe even improve it. That was my plan B back then. Sorry I didn't keep the url to the article on it.

                                                                          There's also another type of chemo with this phase 1 trial NCT02020707. One of it's chemo back in 2009 was being compared with zelboraf. This trial combines it with some others as well.

                                                                          There is also TIL in a phase 2 trial and several phase 1 trials with a rumor of a big trial for it coming in 2015.

                                                                          Also is WDVAX in a phase 1 trial. I have not heard anyone doing it or results but it's pre trial with mice was awesome results. Of course we don't know yet how that will translate to us humans. They are also working on a less invasive delivery system instead of surgical implants they are working on a type of gel to inject the scaffold in with and some other ideas.

                                                                          Also here's an article on the various mutations that makes my head spin:

                                                                          http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=1892&path%5B%5D=2533

                                                                          Artie

                                                                           

                                                                           

                                                                        G-Samsa
                                                                        Participant

                                                                          On the immunotherapy beat I keep hearing about IDO inhibitors and Lag-3 as showing great promise as a next gen treatment.   There is also a chemo-therapy (ADC) that was getting a lot of press at one point–informed by genetics it delivers the cytotoxin directly to the tumor.  It would be nice to have an update on that.  Way down the pike but high on the imaginative scale–Yale Cancer Center has successfully used a virus to attack melanoma in mice (lucky mice).  I believe there are quite a number of other treatments being tested…. 

                                                                      Viewing 2 reply threads
                                                                      • You must be logged in to reply to this topic.
                                                                      About the MRF Patient Forum

                                                                      The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                                                                      The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide byย MRF posting policies.

                                                                      Popular Topics